The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
30 days for final GSK appeal runs out tomorrow. I believe the only option left is the Supreme Court and there is virtually no chance of that happening, so it's either pay up or buy out.
A Few mergers & Acquisitions in the pharma industry
We can Not rule out Vectura as a Target for 2021 with the new management Team
Hugely undervalued at these levels
ReRating will kick in to this Stock
Imminently.
Excellent news & bodes well for 2021 being a pivotal year for our progress following regular disappointment since many of us found ourselves on the share register following the acquisition of SKP.Much positive news to be announced over the coming (hopefully) days, weeks & months.
Presumably the announcement of our CDMO expansion is a measure of confidence of our potential for growth in that division.
Vec upgrades CDMO capabilities
https://endpts.com/vectura-leans-into-new-role-as-inhalation-cdmo-post-asthma-flop-with-expansion-at-england-plant/
Announced today with a US company , which could be the proof that our new CDMO strategy could well be successful- & profitable .
They needed to increase by another 0.1 bill to meet our claim .
Good volume declared after the close -interesting ,as will be the next few weeks ,hopefully
GSK have upped their provisions for legal actions from 0.2b to 0.3b this year - getting ready to pay out?
Vec should put an offer in for synairgen with the cash from GSK. Diversify its portfolio into Covid. Wait for the GSK takeout.
215 would be a good starting point -the next few months could,at last ,herald a new era with generic Advair expecting to hit the market early next year,news due on the development of our generic Elipta range,$32mill from Pacira,hoped for growth in our new CDMO business ,$200mill + from GSK + anything new which is not yet in the public domain
Sadly I am afraid this was already built into the price.
Numis have 140 base case and 290 bull forecast, which in their words is becoming ever more likely because of the new business wins. Making the share a bit of a bargain! They also rate the chances of receiving the payout from GSK at 90%.
By the looks of how things have played out today, I have the feeling that the market believes this upholding of our previous court case is not the end, and until details emerge that GSK have given up their fight our long awaited re-rate is on hold.
am i right in saying the award is over £100m plus all future royalties of 3%? wow!
hi sam i think it should be more. maybe wait for usa to wake up too. they usually make a difference
Pretty muted rise really. Could see another 10-15% once the market wakes up.
this would be a serious increase in the companies net worth imo
predictions for today?
Ah that makes sense then. :)
The verdict was in Bloomberg law before the finish of the day leading to the rise before the RNS
13% Increase in Share Price yesterday before the announcement. Somebody knew something before the release?
140pence on Target
With 200pence later in 2021
This is a one way trading for the Time Being
Good morning every one
As reported in March 2020, Vectura has estimated that damages, accumulated interest and ongoing royalties could amount to approximately $200m in total. The precise amounts to be received are dependent on the future US sales of the infringing products as well as sales for historical periods yet to be reported by GSK.
Will Downie, Chief Executive Officer of Vectura, commented: "We are very pleased with the result of this appeal, which confirms the validity of our intellectual property and the decision to progress this litigation with GSK. Once we have further clarity regarding final settlement and potential timing of receipts, we will provide a further market update."
GlaxoSmithKline PLC has lost an appeal seeking to overturn an $89.7 million verdict a jury handed down after finding that the company's Ellipta line of inhalers infringed a patent belonging to rival drug company Vectura Ltd.
A unanimous three-judge panel of the U.S. Court of Appeals for the Federal Circuit ruled Thursday that there was no grounds to overturn the verdict or to order a new trial, rejecting GSK's arguments that a lower court should have granted it judgment of non-infringement and that a Vectura lawyer made improper statements in court.
Great news
"As reported in March 2020, Vectura has estimated that damages, accumulated interest and ongoing royalties could amount to approximately $200m in total. The precise amounts to be received are dependent on the future US sales of the infringing products as well as sales for historical periods yet to be reported by GSK"
The law is an ass however, even after all this time:
"GSK has 30 days to file a petition for rehearing"